Evidence map›Paper›PMID 35890160›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Design and Anticancer Properties of New Water-Soluble Ruthenium-Cyclopentadienyl Complexes.

Tânia S Morais, Fernanda Marques, Paulo J Amorim Madeira, Maria Paula Robalo, Maria Helena Garcia

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Ru-Controlled Thymine Tautomerization Frozen by a kMolecules (Basel, Switzerland) · 2023
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tânia S MoraisCentro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.ORCID 0000-0003-0233-8243
Fernanda MarquesCentro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Estrada Nacional 10 (km 139,7), 2695-066 Lisboa, Portugal.ORCID 0000-0001-8440-5299
Paulo J Amorim MadeiraAscenza Agro, SA, Av. do Rio Tejo-Parq. Ind. Sapec Bay, 2910-440 Setúbal, Portugal.ORCID 0000-0001-9922-7392
Maria Paula RobaloCentro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.ORCID 0000-0002-8200-6910
Maria Helena GarciaCentro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

Funding

Fundação para a Ciência e Tecnologia CEECIND/00630/2017Fundação para a Ciência e Tecnologia LA/P/0056/2020Fundação para a Ciência e Tecnologia PTDC/QUI-QIN/0146/2020Fundação para a Ciência e Tecnologia UIDB/00100/2020
6 · The paper itself

Abstract

Ruthenium complexes are emerging as one of the most promising classes of complexes for cancer therapy. However, their limited aqueous solubility may be the major limitation to their potential clinical application. In view and to contribute to the progress of this field, eight new water-soluble Ru(II) organometallic complexes of general formula [RuCp(

Indexed as

albuminanticancercyclopentadienylrutheniumwater-soluble

Identifiers

PMID35890160
PMCPMC9321894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.